Simon Fischer

机构：Boehringer Ingelheim (Germany) · ORCID：0000-0002-5188-7620

发表论文 129 篇 · 总被引 3689 次 · h-index 33

代表论文

• The new frontier in CHO cell line development: From random to targeted transgene integration technologies (2024 · Biotechnology Advances · 被引 45)
• Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool (2022 · Journal of Biotechnology · 被引 43)
• High cysteine concentrations in cell culture media lead to oxidative stress and reduced bioprocess performance of recombinant CHO cells (2022 · Biotechnology Journal · 被引 22)
• Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations (2024 · mAbs · 被引 19)
• Polysorbates degrading enzymes in biotherapeutics – a current status and future perspectives (2025 · Frontiers in Bioengineering and Biotechnology · 被引 16)
• Without a trace: multiple knockout of CHO host cell hydrolases to prevent polysorbate degradation in biologics (2025 · Trends in biotechnology · 被引 15)